BioDuro has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic.
The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics experience. The new service offerings, focused on antibody discovery and cellular therapies, include:
- Single B cell and next-generation animal-based Ab discovery. Increase efficiency of clone retrieval, resulting in higher quality antibody ‘hits’ in less time.
- AI powered synthetic Ab technology. Achieve higher efficiency, better developability and overcome the limitation of animal immune systems compared to traditional methods.
- Immune cell therapies. Design, construct and optimize immune cell (e.g. CAR-T) therapies for superior efficacy, safety, and low side effects.
“Antibody- and cell-based therapies are providing some of the most exciting advances in medicine, including unprecedented progress in immune-oncology,” said Xiang Li, DPhil, Senior Vice President, Integrated Biology at BioDuro. “We have carefully developed and validated our biologics discovery services for several years prior to launch. In fact, our early partners have already taken a number of programs we have worked on into the clinic.”